Global CRO footprint OPIS is a global clinical CRO with affiliates in 18 countries and experience managing Phase I-IV, interventional, non-interventional and medical device studies internationally, indicating a broad potential for multinational trial partnerships and cross-border studies.

Broad therapeutic reach With active work across oncology, cardiology, dermatology, neurology, rare diseases, vaccines, gene therapy and more, OPIS serves diverse therapeutic areas, suggesting cross-sell opportunities into multiple departments and increased lifetime value per client.

Full-service capabilities OPIS offers end-to-end trial support from concept and protocol development to data handling and reporting, enabling upsell to clients seeking a single vendor for comprehensive trial management and potential efficiency gains.

Device and nutraceutical focus Beyond traditional drugs, OPIS manages pre- and post-marketing investigations for medical devices, nutraceuticals and dietary supplements, opening sales avenues with device manufacturers and supplement producers expanding into clinical evidence.

Growth and compliance posture With 26 years of operation, a substantial project portfolio (over 1500 studies) and partnerships including data protection collaborations, OPIS signals reliability, scalability and strong governance—appealing to risk-aware sponsors and CRO buyers seeking stability.